NasdaqCM - Nasdaq Real Time Price USD

LakeShore Biopharma Co., Ltd (LSB)

Compare
3.3700 -0.2400 (-6.65%)
As of 1:57 PM EDT. Market Open.

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Gang Li Head of Marketing & Sales -- -- 1982
Dr. Yuan Liu Ph.D. Head of Vaccine Research -- -- 1987
Mr. Wang Xu CEO & Director -- -- 1971
Dr. Hui Shao C.F.A., M.B.A., Ph.D. President, Chief Business Officer & Vice Chairman -- -- 1968
Ms. Rui Yu M.B.A., M.S. CFO & Director -- -- 1975
Dr. Zenaida Reynoso Mojares M.D. Chief Medical Officer -- -- 1959

LakeShore Biopharma Co., Ltd

Building No. 2
38 Yongda Road Daxing Biomedical Industry Park Daxing District
Beijing, 102629
China
86 10 8920 2086 https://www.ysbiopharm.com
Sector:?
Healthcare
Industry:?
Biotechnology
Full Time Employees:?
758

Description

LakeShore Biopharma Co., Ltd, a biopharmaceutical company, engages in the discovering, developing, manufacturing, commercializing, and sale of vaccines and therapeutic biologics for infectious diseases and cancer. The company's product pipeline includes YSJA, a conventional rabies vaccine which is in marketed stage; PIKA, a rabies vaccine which are in phase I/III and preclinical trials for the treatment of rabies virus; PIKA YS-ON-001, an immuno-oncology therapeutic that is in phase I trials for the treatment of pancreatic and hepatocellular cancer; PIKA YS-HBV-001, a hepatitis B vaccine that is in phase I trials; PIKA YS-HBV-002, an immune-therapy vaccine which is in IND preclinical trials for the treatment of chronic HBV infection; and PIKA YS-ON-001 and PIKA Influenza Vaccine which are in preclinical trials. It operates in China, Singapore, the United States, and the Philippines. The company was formerly known as YS Biopharma Co., Ltd. and changed its name to LakeShore Biopharma Co., Ltd in May 2024. The company was founded in 2002 and is based in Beijing, China.

Corporate Governance

LakeShore Biopharma Co., Ltd’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

Recent Events

October 8, 2024 at 12:00 AM UTC

6-K: Corporate Changes & Voting Matters

September 27, 2024 at 12:00 AM UTC

6-K: Corporate Changes & Voting Matters

September 10, 2024 at 12:00 AM UTC

6-K: Corporate Changes & Voting Matters

September 4, 2024 at 12:00 AM UTC

6-K: Corporate Changes & Voting Matters

August 15, 2024 at 12:00 AM UTC

20-F: Periodic Financial Reports

July 31, 2024 at 12:00 AM UTC

NT 20-F: Notice under Rule 12b25 of inability to timely file all or part of an annual report of form 20-F

July 5, 2024 at 12:00 AM UTC

6-K: Corporate Changes & Voting Matters

June 18, 2024 at 12:00 AM UTC

6-K: Corporate Changes & Voting Matters

May 24, 2024 at 12:00 AM UTC

6-K: Corporate Changes & Voting Matters

May 21, 2024 at 12:00 AM UTC

6-K: Corporate Changes & Voting Matters

Related Tickers